<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004548</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-89-1</org_study_id>
    <nct_id>NCT02004548</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Study of Metatinib Tromethamine Tablet</brief_title>
  <official_title>A Phase I, Multiple Dose Escalation Clinical Trial of Metatinib Tromethamine Tablet in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: To evaluate the safety, tolerability and maximum tolerated dose (MTD) of&#xD;
      daily oral administration of metatinib tromethamine in subjects with solid tumors;&#xD;
      Investigate the influence of food on pharmacokinetic parameters.&#xD;
&#xD;
      Secondary Objective: To evaluate the plasma pharmacokinetics (PK) of daily oral&#xD;
      administration of metatinib tromethamine in subjects with solid tumors; To observe&#xD;
      preliminary anti-tumor efficacy; To evaluate potential pharmacodynamic and predictive&#xD;
      biomarkers at MTD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting Toxicity (DLT)</measure>
    <time_frame>up to day 32</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>up to day 32</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>d1、d2、d3、d8、d15、d22、d29、d30、d31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>d1、d2、d3、d8、d15、d22、d29、d30、d31</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>week 4, week 10, week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Metatinib Tromethamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is in accordance with the traditional &quot;3 +3&quot; design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metatinib Tromethamine</intervention_name>
    <arm_group_label>Metatinib Tromethamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Weight: male weight ≥ 45 kg; female weight ≥ 40 kg, body mass index (BMI) between&#xD;
             18~24 kg/m^2, including the boundary values;&#xD;
&#xD;
          -  The subject has a histologically confirmed solid tumor that is metastatic or&#xD;
             unresectable, and for which standard curative or palliative measures do not exist or&#xD;
             are no longer effective, and there are no known therapies to prolong survival;&#xD;
&#xD;
          -  Not treated with standard therapeutical regime currently, or has progressed or&#xD;
             relapsed after standard treatment;&#xD;
&#xD;
          -  Time from last cytotoxic chemotherapy (including investigational cytotoxic agents) or&#xD;
             biologic agents (immune modulators, cytokines) ≥ 4 weeks, or nitrosoureas or mitomycin&#xD;
             C ≥ 6 weeks. If having received an antibody anti-tumor biological product, at least&#xD;
             8-week washout period is required;&#xD;
&#xD;
          -  At least 4 weeks after surgery, and the wound must be healed completely;&#xD;
&#xD;
          -  If subject has chemotherapy-induced toxicity, the adverse events must be recovered to&#xD;
             ≤ grade 1 (NCI-CTC version 4.0) except for alopecia;&#xD;
&#xD;
          -  ECOG performance status of 0-2;&#xD;
&#xD;
          -  Expected survival time is more than three months;&#xD;
&#xD;
          -  The subject has organ and marrow function as follows:&#xD;
&#xD;
               1. absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L,&#xD;
&#xD;
               2. platelets ≥ 80 x 10^9/L,&#xD;
&#xD;
               3. hemoglobin ≥ 90 g/L (blood transfusion is allowed),&#xD;
&#xD;
               4. total bilirubin ≤ 2 x ULN (&lt;3 x ULN with liver metastases),&#xD;
&#xD;
               5. serum creatinine ≤ 150 μmol/L or calculated creatinine clearance ≥ 60 mL/min,&#xD;
&#xD;
               6. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN (&lt;5&#xD;
                  x ULN with liver metastases),&#xD;
&#xD;
               7. uric acid &lt;500 μmol/L,&#xD;
&#xD;
               8. proteinuria ≤ 2 + or ≤ 2g / 24h;&#xD;
&#xD;
          -  The subject is capable of understanding and complying with the protocol and has signed&#xD;
             the informed consent document;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is known to be positive for the human immunodeficiency virus (HIV);&#xD;
&#xD;
          -  The subject is known to be positive for hepatitis B surface antigen or hepatitis C;&#xD;
&#xD;
          -  Previous participation in other clinical trials within three months before study;&#xD;
&#xD;
          -  Concomitant chemotherapy, hormone therapy, immunotherapy program or radiotherapy;&#xD;
&#xD;
          -  The subject has an uncontrolled intercurrent illness including, but not limited to,&#xD;
             ongoing or active infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, or cardiac arrhythmia;&#xD;
&#xD;
          -  The subject has psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements;&#xD;
&#xD;
          -  The subject has brain metastases;&#xD;
&#xD;
          -  Imaging study showed involvement of major blood vessels or nerves by tumor;&#xD;
&#xD;
          -  Uncontrollable hypertension (referring to systolic blood pressure&gt; 150 mmHg and / or&#xD;
             diastolic blood pressure&gt; 100 mmHg after treatment) or LVEF &lt;50%;&#xD;
&#xD;
          -  Patient with disease history of bleeding or thromboembolic events occurred within the&#xD;
             past six months and need for preventive anticoagulant therapy;&#xD;
&#xD;
          -  Patient needs surgery within 28 days, or is expected to require surgery within 28 days&#xD;
             after the last dose administration;&#xD;
&#xD;
          -  Significant abnormality in the important organs, such as heart, lung, liver, kidney;&#xD;
&#xD;
          -  Has third lacunar effusion with difficulty to control;&#xD;
&#xD;
          -  The subject is pregnant or breastfeeding;&#xD;
&#xD;
          -  Sexually active subjects (male and female) refuse to use medically acceptable methods&#xD;
             of contraception during the course of the study and for 1 month following&#xD;
             discontinuation of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Bi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maozhi Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>You Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qin Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Li Zheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

